文献速递细菌感染、耐药与抗菌药物

硝唑尼特增强利奈唑胺对利奈唑胺耐药金黄色葡萄球菌的体内外活性

Nitazoxanide potentiates linezolid against linezolid-resistant Staphylococcus aureus in vitro and in vivo.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

研究通过全细胞筛选FDA批准药物发现硝唑尼特具有抗金黄色葡萄球菌活性,体外对临床耐药菌株与肠球菌属活性相当,浓度依赖性杀菌、显著清除预形成生物膜且不产生耐药;硝唑尼特与利奈唑胺在体内外对利奈唑胺敏感和耐药金黄色葡萄球菌均呈强协同,优于未治疗对照和单药治疗组。

要点

  • 硝唑尼特对临床耐药金黄色葡萄球菌和肠球菌属显示等效的体外活性。
  • 硝唑尼特呈浓度依赖性杀菌,显著清除预形成金黄色葡萄球菌生物膜,金黄色葡萄球菌未对其产生耐药。
  • 硝唑尼特与利奈唑胺在体内外对利奈唑胺敏感和耐药金黄色葡萄球菌均呈强协同。

核心结论

  • 硝唑尼特可与利奈唑胺联合用于治疗利奈唑胺耐药金黄色葡萄球菌所致感染,因在体内外均显示强协同作用。

研究设计与样本

  • 采用全细胞试验筛选FDA批准药物以识别对细菌病原体有活性的新型抗菌药物。
  • 鉴定硝唑尼特后,测定其抗MDR分离株活性、时间-杀菌动力学、与已批准药物协同能力、抗生物膜活性及诱导金黄色葡萄球菌产生耐药的能力,随后测定其针对MDR金黄色葡萄球菌的体内潜力。

主要发现

  • 硝唑尼特表现出强效体外抗葡萄球菌活性,包括对临床耐药金黄色葡萄球菌和肠球菌属的等效活性。
  • 硝唑尼特呈浓度依赖性杀菌,显著清除预形成的金黄色葡萄球菌生物膜,且金黄色葡萄球菌未对其产生耐药。
  • 硝唑尼特与利奈唑胺在体外和体内对利奈唑胺敏感和耐药金黄色葡萄球菌均呈强协同,活性优于未治疗对照组和单药治疗组。

临床怎么用

  • 作者认为硝唑尼特可与利奈唑胺联合用于治疗利奈唑胺耐药金黄色葡萄球菌所致感染。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antimicrobial resistance is a growing menace, claiming millions of lives all over the world. In this context, drug repurposing is one approach gaining interest as a suitable alternative to conventional drug discovery and development. METHODS: Whole-cell assays were used to screen FDA-approved drugs to identify novel antimicrobial agents active against bacterial pathogens. Following identification of nitazoxanide, its various characteristics, such as antimicrobial activity against MDR isolates, time-kill kinetics, ability to synergize with approved drugs, antibiofilm activity and ability to generate resistance in Staphylococcus aureus, were determined, followed by determination of its in vivo potential against MDR S. aureus. RESULTS: Nitazoxanide demonstrated a potent in vitro antistaphylococcal profile, including equipotent activity against clinical drug-resistant S. aureus and Enterococcus spp. Nitazoxanide exhibited concentration-dependent killing, significantly eradicated preformed S. aureus biofilm and S. aureus did not generate resistance to it. Nitazoxanide strongly synergized with linezolid both in vitro and in vivo against linezolid-susceptible and -resistant S. aureus, displaying superior activity to untreated control and drug-alone treatment groups. CONCLUSIONS: Nitazoxanide can be utilized in combination with linezolid against infections caused by linezolid-resistant S. aureus as it exhibits strong synergism in vitro and in vivo.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Kaul G, Akhir A, Shukla M, et al. Nitazoxanide potentiates linezolid against linezolid-resistant Staphylococcus aureus in vitro and in vivo. J Antimicrob Chemother. 2022. PMID: 35748613. doi:10.1093/jac/dkac201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。